NCT02351102View on ClinicalTrials.gov

Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Congenital Cytomegalovirus Infection
Interventions
DRUG

Valacyclovir

DRUG

Placebo

Trial Locations (1)

Unknown

Helen Schneider Hospital for Women, Petah Tikva

All Listed Sponsors
lead

Rabin Medical Center

OTHER

NCT02351102 - Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy | Biotech Hunter | Biotech Hunter